Influence of COVID-19 vaccines on endocrine system.
COVID-19 vaccine
Endocrine dysfunction
Side effects
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
30
03
2022
accepted:
14
06
2022
pubmed:
26
6
2022
medline:
25
10
2022
entrez:
25
6
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic has posed a significant health threat globally. Timely and appropriate vaccination is a key step to reduce the morbidity and mortality from COVID-19. The clinical course of COVID-19 infection and the effects of COVID-19 vaccination are influenced by patients' health situations and involve a systemic physiological reaction. Just like an "endocrine phenotype" of COVID-19 infection, endocrine dysfunction after COVID-19 vaccination also acquired clinical concerns. In the present review, we briefly introduce the commonly available vaccines against SARS-CoV-2, summarize the influence of COVID-19 vaccines on the endocrine system, and explore the underlying pathogenic mechanisms.
Identifiants
pubmed: 35751776
doi: 10.1007/s12020-022-03119-3
pii: 10.1007/s12020-022-03119-3
pmc: PMC9244486
doi:
Substances chimiques
COVID-19 Vaccines
0
Viral Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
241-246Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
E.J. Williamson, A.J. Walker, K. Bhaskaran, S. Bacon, C. Bates et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430–436 (2020)
pubmed: 32640463
pmcid: 7611074
doi: 10.1038/s41586-020-2521-4
C. Kreer, M. Zehner, T. Weber, M.S. Ercanoglu, L. Gieselmann et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell 182, 843–854.e812 (2020)
pubmed: 32673567
pmcid: 7355337
doi: 10.1016/j.cell.2020.06.044
W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020)
pubmed: 32109013
doi: 10.1056/NEJMoa2002032
I.H. Elrobaa, K.J. New, COVID-19: pulmonary and extra pulmonary manifestations. Front. public health 9, 711616 (2021)
pubmed: 34650947
pmcid: 8505777
doi: 10.3389/fpubh.2021.711616
S.A. Clarke, A. Abbara, W.S. Dhillo, Impact of COVID-19 on the endocrine system: a mini-review. Endocrinology 163, 1–20 (2022).
doi: 10.1210/endocr/bqab203
A.K. Murugan, A.S. Alzahrani, SARS-CoV-2: emerging role in the pathogenesis of various thyroid diseases. J. Inflamm. Res. 14, 6191–6221 (2021)
pubmed: 34853527
pmcid: 8628126
doi: 10.2147/JIR.S332705
J.K. Yang, S.S. Lin, X.J. Ji, L.M. Guo, Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 47, 193–199 (2010)
pubmed: 19333547
doi: 10.1007/s00592-009-0109-4
F. Liu, X. Long, B. Zhang, W. Zhang, X. Chen et al. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin. Gastroenterol. Hepatol. 18, 2128–2130.e2122 (2020)
pubmed: 32334082
pmcid: 7194639
doi: 10.1016/j.cgh.2020.04.040
A.K. Murugan, A.S. Alzahrani, SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves’ disease. Endocrine 73, 243–254 (2021)
pubmed: 34106438
pmcid: 8188762
doi: 10.1007/s12020-021-02770-6
L. Zhu, Z.G. She, X. Cheng, J.J. Qin, X.J. Zhang et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 31, 1068–1077.e1063 (2020)
pubmed: 32369736
pmcid: 7252168
doi: 10.1016/j.cmet.2020.04.021
M. Puig-Domingo, M. Marazuela, B.O. Yildiz, A. Giustina, COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine 72, 301–316 (2021)
pubmed: 33963516
pmcid: 8105151
doi: 10.1007/s12020-021-02734-w
A. Giustina, Hypovitaminosis D and the endocrine phenotype of COVID-19. Endocrine 72, 1–11 (2021)
pubmed: 33738708
pmcid: 7972333
doi: 10.1007/s12020-021-02671-8
S.M. Mung, E.B. Jude, Interplay between endocrinology, metabolism and COVID-19 infection. Clin. Med. 21, e499–e504 (2021)
doi: 10.7861/clinmed.2021-0200
L.R. Baden, H.M. El Sahly, B. Essink, K. Kotloff, S. Frey et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021)
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
C.B. Creech, S.C. Walker, R.J. Samuels, SARS-CoV-2 vaccines. JAMA 325, 1318–1320 (2021)
pubmed: 33635317
doi: 10.1001/jama.2021.3199
K. Subbarao, The success of SARS-CoV-2 vaccines and challenges ahead. Cell Host Microbe 29, 1111–1123 (2021)
pubmed: 34265245
pmcid: 8279572
doi: 10.1016/j.chom.2021.06.016
Q. Gao, L. Bao, H. Mao, L. Wang, K. Xu et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020)
pubmed: 32376603
doi: 10.1126/science.abc1932
R. Ella, K.M. Vadrevu, H. Jogdand, S. Prasad, S. Reddy et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect. Dis. 21, 637–646 (2021)
pubmed: 33485468
pmcid: 7825810
doi: 10.1016/S1473-3099(20)30942-7
M.S. Jeeyavudeen, A.W. Patrick, F.W. Gibb, A.R. Dover, COVID-19 vaccine-associated subacute thyroiditis: an unusual suspect for de Quervain’s thyroiditis. BMJ Case Rep. 14, 1–3 (2021).
doi: 10.1136/bcr-2021-246425
J. Schimmel, E.L. Alba, A. Chen, M. Russell, R. Srinath, Thyroiditis and thyrotoxicosis after the SARS-CoV-2 mRNA vaccine. Thyroid 31, 1440 (2021).
pubmed: 34030467
doi: 10.1089/thy.2021.0184
B.G. İremli, S.N. Şendur, U. Ünlütürk, Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: postvaccination ASIA syndrome. J. Clin. Endocrinol. Metab. 106, 2600–2605 (2021)
pubmed: 34043800
doi: 10.1210/clinem/dgab373
F.A. Altay, G. Güz, M. Altay, Subacute thyroiditis following seasonal influenza vaccination. Hum. Vaccines Immunother. 12, 1033–1034 (2016)
doi: 10.1080/21645515.2015.1117716
J.Y. Hsiao, S.C. Hsin, M.C. Hsieh, P.J. Hsia, S.J. Shin, Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female. Kaohsiung J. Med. Sci. 22, 297–300 (2006)
pubmed: 16793568
doi: 10.1016/S1607-551X(09)70315-8
C. Sriphrapradang, P.C. Shantavasinkul, Graves’ disease following SARS-CoV-2 vaccination. Endocrine 74, 473–474 (2021)
pubmed: 34648112
pmcid: 8514605
doi: 10.1007/s12020-021-02902-y
G. Zettinig, M. Krebs, Two further cases of Graves’ disease following SARS-Cov-2 vaccination. J. Endocrinol. Investig. 45, 227–228 (2022)
doi: 10.1007/s40618-021-01650-0
K.A. Lee, Y.J. Kim, H.Y. Jin, Thyrotoxicosis after COVID-19 vaccination: seven case reports and a literature review. Endocrine 74, 470–472 (2021)
pubmed: 34637073
pmcid: 8507356
doi: 10.1007/s12020-021-02898-5
A. Siolos, K. Gartzonika, S. Tigas, Thyroiditis following vaccination against COVID-19: Report of two cases and review of the literature. Metab. Open 12, 100136 (2021)
doi: 10.1016/j.metop.2021.100136
A. Mishra, A. Ghosh, K. Dutta, K. Tyagi, A. Misra, Exacerbation of hyperglycemia in patients with type 2 diabetes after vaccination for COVID19: report of three cases. Diabetes Metab. Syndr. 15, 102151 (2021)
pubmed: 34186339
pmcid: 8143905
doi: 10.1016/j.dsx.2021.05.024
A.H. Heald, M. Stedman, L. Horne, R. Rea, M. Whyte et al. Analysis of continuous blood glucose data in people with type 1 diabetes (T1DM) after COVID-19 vaccination indicates a possible link between the immune and the metabolic response. J. Diabetes Sci. Technol. 15, 1204–1205 (2021)
pubmed: 34323111
pmcid: 8411469
doi: 10.1177/19322968211026291
A.E. Edwards, R. Vathenen, S.M. Henson, S. Finer, K. Gunganah, Acute hyperglycaemic crisis after vaccination against COVID-19: a case series. Diabet. Med. 38, e14631 (2021)
pubmed: 34185927
pmcid: 8420566
doi: 10.1111/dme.14631
M.A. Abu-Rumaileh, A.M. Gharaibeh, N.E. Gharaibeh, COVID-19 vaccine and hyperosmolar hyperglycemic state. Cureus 13, e14125 (2021)
pubmed: 33927933
pmcid: 8075828
H.J. Lee, A. Sajan, Y. Tomer, Hyperglycemic emergencies associated With COVID-19 vaccination: a case series and discussion. J. Endocr. Soc. 5, bvab141 (2021)
pubmed: 34604689
pmcid: 8477915
doi: 10.1210/jendso/bvab141
N. Murvelashvili, A. Tessnow, A case of hypophysitis following immunization with the mRNA-1273 SARS-CoV-2 vaccine. J. Investig Med. High. Impact Case Rep. 9, 23247096211043386 (2021)
pubmed: 34553641
pmcid: 8474296
P. Taylor, L. Allen, N. Shrikrishnapalasuriyar, M. Stechman, A. Rees, Vaccine-induced thrombosis and thrombocytopenia with bilateral adrenal haemorrhage. Clin. Endocrinol. 97, 26–27 (2021).
doi: 10.1111/cen.14548
J.F. Varona, M. García-Isidro, M. Moeinvaziri, M. Ramos-López, M. Fernández-Domínguez, Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT). Eur. J. Intern. Med. 91, 90–92 (2021)
pubmed: 34256983
pmcid: 8271354
doi: 10.1016/j.ejim.2021.06.025
Y. Shoenfeld, Video Q&A: what is ASIA? An interview with Yehuda Shoenfeld. BMC Med. 11, 118 (2013)
pubmed: 23635355
pmcid: 3662178
doi: 10.1186/1741-7015-11-118
R.L. Coffman, A. Sher, R.A. Seder, Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492–503 (2010)
pubmed: 21029960
pmcid: 3420356
doi: 10.1016/j.immuni.2010.10.002
N.L. Bragazzi, A. Hejly, A. Watad, M. Adawi, H. Amital et al. ASIA syndrome and endocrine autoimmune disorders. Best. Pract. Res. Clin. Endocrinol. Metab. 34, 101412 (2020)
pubmed: 32265102
doi: 10.1016/j.beem.2020.101412
Z. Liang, H. Zhu, X. Wang, B. Jing, Z. Li et al. Adjuvants for coronavirus vaccines. Front. Immunol. 11, 589833 (2020)
pubmed: 33240278
pmcid: 7677582
doi: 10.3389/fimmu.2020.589833
L.H. Garvey, S. Nasser, Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br. J. Anaesth. 126, e106–e108 (2021)
pubmed: 33386124
doi: 10.1016/j.bja.2020.12.020
S.O. Oyibo, Subacute thyroiditis after receiving the adenovirus-vectored vaccine for coronavirus disease (COVID-19). Cureus 13, e16045 (2021)
pubmed: 34235030
pmcid: 8242270
A. Dotan, S. Muller, D. Kanduc, P. David, G. Halpert et al. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 20, 102792 (2021)
pubmed: 33610751
pmcid: 7892316
doi: 10.1016/j.autrev.2021.102792
O. Vera-Lastra, A. Ordinola Navarro, M.P. Cruz Domiguez, G. Medina, T.I. Sánchez Valadez et al. Two cases of graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid. 31, 1436–1439 (2021)
pubmed: 33858208
doi: 10.1089/thy.2021.0142
B. Liu, M. Li, Z. Zhou, X. Guan, Y. Xiang, Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J. Autoimmun. 111, 102452 (2020)
pubmed: 32291137
pmcid: 7151347
doi: 10.1016/j.jaut.2020.102452
D.C. Fajgenbaum, C.H. June, Cytokine storm. N. Engl. J. Med. 383, 2255–2273 (2020)
pubmed: 33264547
pmcid: 7727315
doi: 10.1056/NEJMra2026131
J.W. Park, S.N. Yu, S.H. Chang, Y.H. Ahn, M.H. Jeon, Multisystem inflammatory syndrome in an adult after COVID-19 vaccination: a case report and literature review. J. Korean Med. Sci. 36, e312 (2021)
pubmed: 34811978
pmcid: 8608920
doi: 10.3346/jkms.2021.36.e312
J.A. Müller, R. Groß, C. Conzelmann, J. Krüger, U. Merle et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat. Metab. 3, 149–165 (2021)
pubmed: 33536639
doi: 10.1038/s42255-021-00347-1
T. Sathish, R.J. Tapp, M.E. Cooper, P. Zimmet, Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab. 47, 101204 (2021)
pubmed: 33129968
doi: 10.1016/j.diabet.2020.10.002
C.T. Wu, P.V. Lidsky, Y. Xiao, I.T. Lee, R. Cheng et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 33, 1565–1576.e1565 (2021)
pubmed: 34081912
pmcid: 8130512
doi: 10.1016/j.cmet.2021.05.013
H.C. Meissner, Understanding vaccine safety and the roles of the FDA and the CDC. N. Engl. J. Med. 386, 1638–1645 (2022)
pubmed: 35476652
pmcid: 9069993
doi: 10.1056/NEJMra2200583
M. Sözen, Ö. Topaloğlu, B. Çetinarslan, A. Selek, Z. Cantürk et al. COVID-19 mRNA vaccine may trigger subacute thyroiditis. Hum. Vaccines Immunother. 17, 5120–5125 (2021)
doi: 10.1080/21645515.2021.2013083
C. Bornemann, K. Woyk, C. Bouter, Case report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination. Front. Med. 8, 737142 (2021)
doi: 10.3389/fmed.2021.737142
C. Sriphrapradang, Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease. Endocrine 74, 226–227 (2021)
pubmed: 34533769
pmcid: 8447113
doi: 10.1007/s12020-021-02879-8
H. Bostan, B. Ucan, M. Kizilgul, M. Calapkulu, S. Hepsen et al. Relapsed and newly diagnosed Graves’ disease due to immunization against COVID-19: a case series and review of the literature. J. Autoimmun. 128, 102809 (2022)
pubmed: 35220164
pmcid: 8867370
doi: 10.1016/j.jaut.2022.102809